The development of xenograft

异种移植的发展

基本信息

  • 批准号:
    05557065
  • 负责人:
  • 金额:
    $ 12.86万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
  • 财政年份:
    1993
  • 资助国家:
    日本
  • 起止时间:
    1993 至 1995
  • 项目状态:
    已结题

项目摘要

We established several swine endothelial cell (SEC) lines, expressing human MCP,DAF,and an MCP/DAF hybrid by transfection of cDNA,and assessed the function of these transfectant molecules on C-mediated cell lysis as an in vitro hyperacute rejection model of swine to human discordant xenograft.1) DAF is quite effective to protect SEC from C-mediated cell lysis. Especially, over 80% suppression was observed in high expression clone. On the other hand, MCP is also effective in suppressing C activity, but the less efficient as the C3-step regulator than DAF.Hybrid showed approximate 60% of suppression of C-mediated cell lysis. It is more effective than MCP alone clearly, but indistinct from DAF alone because of the difference in the expression rate of transfectant molecules in each clone.2) CD59 is effective in protection of SEC when it is sufficiently expressed. However, DC59 is not so efficient in protecting SEC membrane from human C attack as DAF,because SEC is lysed at the C5b-8 step of the human complement cascade.TRANSGENICTo obtain the transgenic animals expressing human-MCP at high level, several studies concerning the promoter and enhancer have done. We obtained 11 independent lines of MCP transgenic mice lacking just the polyA signal and 5 lines without the entire 3'UT,as assessed by PCR and Southern blotting. While the expression of MCP in mice carrying MCP cDNA with 120bp of 3'UT was minimal, that in mice carrying MCP cDNA without total 3'UT was evident in many organs ; especially in muscle, heart, and pancreas.
我们建立了几个猪内皮细胞(SEC)系,表达人MCP,MCP,和MCP/MCP杂合体的cDNA转染,并评估这些转染分子对C介导的细胞溶解的功能,作为猪对人不协调异种移植物的体外超急性排斥模型。1)MCP是非常有效的保护SEC免受C介导的细胞溶解。特别是在高表达克隆中,观察到超过80%的抑制。另一方面,MCP在抑制C活性方面也是有效的,但是作为C3步骤调节剂的效率低于C3步骤调节剂。它明显比单独的MCP更有效,但由于每个克隆中转染分子表达率的差异,与单独的MCP的区别不明显。2)当CD 59充分表达时,它在SEC的保护中是有效的。然而,由于SEC在人补体级联反应的C5 b-8步骤被裂解,因此DC 59在保护SEC膜免受人C攻击方面不如人MCP有效。我们获得了11个单独的MCP转基因小鼠品系,仅缺乏polyA信号,5个品系没有整个3 'UT,如通过PCR和Southern印迹所评估的。尽管在携带有120 bp的3 'UT的MCP cDNA的小鼠中MCP的表达是最小的,但在携带MCP cDNA而没有总3' UT的小鼠中,MCP在许多器官中的表达是明显的,特别是在肌肉、心脏和胰腺中。

项目成果

期刊论文数量(33)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Shuji Miyagawa: "C5b-8 Step lysis of swine endothelial cells by human complement and functional feature of CD59." Scand. J. Immunol.(in press).
Shuji Miyakawa:“通过人类补体和 CD59 的功能特征对猪内皮细胞进行 C5b-8 步骤裂解。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.Miyagawa: "Test for ability of decay-accelerating factor(DAF,CD55)and CD59to alleviate complement-mediated damage of xeno-erythrocytes." Scand.J.Immunol.38. 37-44 (1993)
S.Miyakawa:“测试衰变加速因子(DAF、CD55)和 CD59 减轻补体介导的异种红细胞损伤的能力。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.Miyagawa: "Prolonging discordant xenograft survival with anticomplement reagents,K76COOH and FUT175." Transplantation. 55. 709-713 (1993)
S.Miyakawa:“用抗补体试剂 K76COOH 和 FUT175 延长不一致的异种移植物存活。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.Miyagawa,R.Shirakura,et al.: "EFFECT OF TRANSFECTANT MOLECULES,MCP,DAF,AND MCP/DAF HYBRID ON XENOGENIC VASCULAR ENDOTHELIUM" Transplantation Proccedings. (in press). (1994)
S.Miyakawa,R.Shirakura,等人:“转染分子、MCP、DAF 和 MCP/DAF 混合物对异种血管内皮的影响”移植程序。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S Miyagawa, R Shirakura, G Matsumiya, S Nakata, H Matsuda, M Matsumoto, H Kitamura, and T Seya.: "Test for ability of decay-accelerating factor (DAF,CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes." Scand.J.Immunol.38. 37-44 (1
S Miyakawa、R Shirakura、G Matsumiya、S Nakata、H Matsuda、M Matsumoto、H Kitamura 和 T Seya。:“测试腐烂加速因子(DAF、CD55)和 CD59 减轻补体介导的异种损伤的能力
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHIRAKURA Ryota其他文献

SHIRAKURA Ryota的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHIRAKURA Ryota', 18)}}的其他基金

Downregulation of the NK cell activity on xenograft
异种移植物上 NK 细胞活性的下调
  • 批准号:
    15390414
  • 财政年份:
    2003
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The strategy for inhibiting NK cell activity by gene technology
利用基因技术抑制NK细胞活性的策略
  • 批准号:
    12470273
  • 财政年份:
    2000
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
A study of molecular diagnosis and treatment for chronic cardiac allograft rejection.
慢性心脏同种异体移植排斥反应的分子诊断和治疗研究。
  • 批准号:
    10557122
  • 财政年份:
    1998
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
A study for the in vivo mechanism of transplantation tolerance using GFP transgenic mice
GFP转基因小鼠体内移植耐受机制研究
  • 批准号:
    10470274
  • 财政年份:
    1998
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The study elucidating the molecular mechanisms underlying transplant vasculopathy
该研究阐明了移植血管病变的分子机制
  • 批准号:
    08457349
  • 财政年份:
    1996
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
ESTABLISHMENT OF IMMUNOSUPPRRESIVE METHOD FOR CLINICAL XENOTRANSPLANTATION
临床异种移植免疫抑制方法的建立
  • 批准号:
    06454400
  • 财政年份:
    1994
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
The Clonal Analysis of Effector Mechanism in Graft Rejection
移植物排斥效应机制的克隆分析
  • 批准号:
    01570710
  • 财政年份:
    1989
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

Complement C6蛋白抑制DNA损伤修复增敏甲状腺乳头状癌放射性碘治疗的作用及其机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
  • 批准号:
    MR/Y000854/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Fellowship
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
  • 批准号:
    10751872
  • 财政年份:
    2024
  • 资助金额:
    $ 12.86万
  • 项目类别:
NSF Convergence Accelerator, Track M: TANDEM: Tensegrity-based Assistive aND rehabilitation Exosuits to complement human bioMechanics
NSF 融合加速器,轨道 M:TANDEM:基于张拉整体的辅助和康复外装,以补充人体生物力学
  • 批准号:
    2344385
  • 财政年份:
    2024
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Standard Grant
Development of a novel oral vaccine for fish: Synergy of chitosan nano particle and complement-mediated opsonization
新型鱼类口服疫苗的开发:壳聚糖纳米颗粒与补体介导的调理作用的协同作用
  • 批准号:
    24K17960
  • 财政年份:
    2024
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Crosstalk between purinergic signaling and the complement system in sepsis-induced immunosuppression.
脓毒症引起的免疫抑制中嘌呤能信号传导与补体系统之间的串扰。
  • 批准号:
    23H03013
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Complement Protein C1q Regulation of Macrophage Metabolic Pathways
补体蛋白 C1q 对巨噬细胞代谢途径的调节
  • 批准号:
    10629550
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
Lung-derived complement in pneumonia
肺炎中的肺源性补体
  • 批准号:
    10568567
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection
急性至持续性风疹病毒感染期间获得的补体耐药性
  • 批准号:
    10645486
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
Defining the impact of complement inhibition by tick saliva in tick-borne virus evolution and adaptive immune responses in murine models of infection
定义蜱唾液抑制补体对蜱传病毒进化和小鼠感染模型适应性免疫反应的影响
  • 批准号:
    10535945
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease
VCP 抑制补体途径治疗阿尔茨海默病
  • 批准号:
    10602757
  • 财政年份:
    2023
  • 资助金额:
    $ 12.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了